Literature DB >> 22429755

Atypical forms of Guillain-Barré syndrome and H1N1-influenza vaccination.

Aasef G Shaikh1, Pichet Termsarasab, Chinasa Nwankwo, Anitha Rao-Frisch, Bashar Katirji.   

Abstract

Recent epidemiological studies established extremely rare incidence of Guillain-Barre syndrome (GBS) after contemporary H1N1-influenza vaccine. We saw five patients with 'atypical' GBS variants that started within four weeks of 2010/2011 H1N1-influenza vaccine. There was no evidence for other etiologies of GBS. The patients presented with sensory ataxia, areflexia, extremity and oropharyngeal paresthesias, numbness, pain, weakness, sphincteric disturbances, and dysautonomia. One patient had Miller Fisher syndrome. All had elevated cerebrospinal fluid protein, and classic electrodiagnostic finding suggestive of GBS. All received the treatment with intravenous immunoglobulin with variable response. These pilot observations suggest that H1N1-influenza vaccine may be associated with rare and atypical variants of GBS. However, epidemiological studies with large cohorts are necessary to confirm excess cases of atypical GBS after H1N1-influenza vaccination.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429755     DOI: 10.1016/j.vaccine.2012.03.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Miller-Fisher Syndrome and Guillain-Barre Syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination.

Authors:  Yew Li Dang; Alexander Bryson
Journal:  BMJ Case Rep       Date:  2021-11-30

2.  Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.

Authors:  Sharon K Greene; Melisa D Rett; Claudia Vellozzi; Lingling Li; Martin Kulldorff; S Michael Marcy; Matthew F Daley; Edward A Belongia; Roger Baxter; Bruce H Fireman; Michael L Jackson; Saad B Omer; James D Nordin; Robert Jin; Eric S Weintraub; Vinutha Vijayadeva; Grace M Lee
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

3.  Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.

Authors:  Odile Launay; Xavier Duval; Serge Fitoussi; Wolfgang Jilg; Angkool Kerdpanich; May Montellano; Tino F Schwarz; Veerachai Watanveerade; Jürgen J Wenzel; Gerard Zalcman; Vinod Bambure; Ping Li; Adrian Caplanusi; Anuradha Madan; Paul Gillard; David W Vaughn
Journal:  BMC Infect Dis       Date:  2013-09-16       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.